The super generics market was valued at USD 235.6 billion in 2025, is projected to reach USD 474.6 billion by 2035 and is forecast to register a 7.2% CAGR between 2025 and 2035. In 2025, oral solid dosage forms hold 23% of drug type demand and oncology represents 40% of therapeutic area sales.